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Abstract
Objectives: Anti-müllerian hormone (AMH) is a marker of ovarian reserve. The purpose of this study was to compare
AMH in women living with HIV with an age-matched control group of HIV-uninfected women, and to identify possible
variables associated with decreasing AMH levels in women living with HIV.
Methods: AMH was measured in frozen EDTA samples from 84 white women living with HIV, aged 20 –40 years, with
fully suppressed HIV RNA viral loads for at least 6 months and no hepatitis B or C virus co-infection. All women living
with HIV were age-matched with HIV-uninfected control women.
Results: Eighty-four women living with HIV and 252 control women were included. Median age for the women living
with HIV was 33.5 years (interquartile range [IQR] 30.6−35.3), and 33.2 years (IQR 30.6−35.5) for the control women.
A significant difference (P=0.03) was found in the mean AMH levels for all age groups combined, which was 17.23 pmol/L
(95% confidence interval [CI] 14.56−19.89) in the women living with HIV versus 21.65 pmol/L (95% CI 19.50−23.81)
in the control women, although levels were within reference limits in both groups.
Only increasing age was significantly associated with decreasing AMH levels and not CD4 cell count, AIDS prior to inclusion,
antiretroviral treatment/lack of treatment or antiretroviral treatment regimen.
Conclusions: Well-treated, white women living with HIV in Denmark, have reduced AMH levels compared with age-matched
control HIV-uninfected women. The only variable associated with decreasing AMH levels in women living with HIV was
increasing age.
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Introduction
Ovarian reserve can be assessed by measuring the dimeric glycoprotein
anti-müllerian hormone (AMH), which is secreted by granulosa cells
from birth to menopause [1]. AMH can be measured in blood and
is used as a reliable marker of the female ovarian reserve [1–3].
Only a few studies have been conducted on AMH in women living
with HIV, with diverging conclusions [4–9]. A French study from
2009 showed a reduction in age-adjusted AMH levels among fully
suppressed women living with HIV [5]. In contrast, an American
study from 2014 showed that in fully suppressed women living
with HIV, AMH levels were higher than in HIV-uninfected control
women, after adjustment for CD4 cell counts [6]. Another American
study showed that AMH may be used for prediction of age at
menopause in women living with HIV [10].
When interpreting the studies on AMH levels, it is also important
to be aware that the earlier generation I assays have been criticised
for lack of precision and low sensitivity [11,12]. Specifically, there
have been concerns regarding complement interfering with the
analysis [11]. We have therefore used the newly developed, fully
automated Elecsys AMH assay (Roche, Rotkreuz, Switzerland) to
analyse AMH levels in our study [12].
The objective of the present study was to estimate AMH using a
fully automated precision assay in white women living with HIV,
with fully suppressed HIV RNA, in comparison with a very well
defined control group of age-matched, HIV-uninfected healthy
women. Moreover, we wanted to identify possible variables
associated with decreasing AMH levels in women living with HIV.
Methods
Study population
Denmark, with a population of 5.6 million people, offers free access
to healthcare, including antiretroviral treatment [13,14]. There are
1400 women living with HIV in Denmark, half of whom are
immigrants, and mode of infection is predominantly through
heterosexual exposure [15–17].
Women living with HIV were identified in the Danish HIV Cohort
study (DHCS), which is an ongoing, nationwide, prospective,
observational, multicentre, population-based cohort study of all
individuals living with HIV seen at Danish departments of infectious
diseases since 1 January 1995 [13].
Eligible participants were white women living with HIV, aged 20–40
years, with at least 6 months of fully suppressed viral load (<50
copies HIV RNA/mL), without hepatitis B or C virus co-infection,
attending either theDepartment of InfectiousDiseases, Copenhagen
University Hospital, Hvidovre or Copenhagen University Hospital,
Rigshospitalet, andwith available stored frozen EDTAplasma samples
between December 1997 and September 2016.
Differences in AMH levels in women of different ethnicities have
previously been reported, and because the control women were
of European origin, consequently, only white women living with
HIV were included in the study [9]. A flow chart of the inclusion
process is shown in Figure 1.
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After eligible women living with HIV were found, their medical
charts were reviewed in order to exclude women living with HIV
who, at time of blood sampling, were pregnant, had gone through
previous surgical procedures on the female reproductive organs,
or had a diagnosis of gynaecological cancer. Information on CD4
cell counts, HIV RNA, place of birth, year of HIV diagnosis, mode
of transmission, region of transmission, antiretroviral treatment
and acquired immunodeficiency syndrome (AIDS) diagnoses was
obtained from the DHCS. No information about BMI, menstrual
history, fertility history or smoking habits was available.
Control women
Hospital white female employees, aged 20–40 years, were included
at Copenhagen University Hospital, Rigshospitalet, from August
2008 to February 2010 (previously described [18]) for AMH
measurement. Exclusion criteria were: pregnancy at time of the
physical examination, use of hormonal contraception, amenorrhea
or clinical hirsutism, previous ovarian surgery, presence of ovarian
cysts or gynaecological cancer.
Pilot study participants
To compare serum to EDTA samples, 10 women living with HIV
attending regular outpatient follow-up at the Department of
Infectious Diseases, Copenhagen University Hospital, Hvidovre,
were enrolled in a pilot study. In these women, AMH levels were
measured in paired EDTA plasma and serum samples, to evaluate
a possible difference in AMH levels. The manufacturer recommends
using heparin plasma or serum as EDTA sampling has been shown
to produce 10% higher results [19,20].
For the pilot study participants, written information was given and
informed consent was achieved prior to blood sampling.
Anti-müllerian hormone assay
Blood samples from people living with HIV, who have consented
to the use of their biological material for research, are stored in
two biobanks: Copenhagen University Hospitals, Hvidovre and
Rigshospitalet. Samples (EDTA plasma) of 0.5−1.5 mL are taken
at regular outpatient clinic visits: once yearly at Copenhagen
University Hospital, Hvidovre and twice yearly at Copenhagen
University Hospital, Rigshospitalet. Samples are either immediately
frozen at −20°C for the first few weeks, and subsequently stored
at −80°C, or centrifuged and frozen at −80°C after 24−48 hours.
Some samples may have been thawed and re-frozen. The samples
included in this study have been stored between 4 and 19 years.
No information concerning collection of blood samples in relation
to the women‘s menstrual cycles was available, although this would
not have changed the AMH level in the blood samples [1].
Frozen EDTA plasma samples were thawed and analysed (on 10
August 2016) at the Department of Clinical Biochemistry,
Copenhagen University Hospital, Hvidovre, using the new Elecsys
AMH assay according to the manufacturer‘s instructions [21].
During the autumn of 2015, frozen serum samples from the control
women were analysed using the new Elecsys AMH assay at the
Department of Clinical Biochemistry, Copenhagen University
Hospital, Rigshospitalet.
Statistical analysis
Categorical variables were reported as absolute and relative
frequencies. Continuous variables were summarised as median and
interquartile ranges (IQR). Dependent group t-test was performed
for the pilot study analysis, comparing AMH levels measured in
paired serum and EDTA samples.
Women living with HIV were matched on age (+/− 3.5 years) with
control women (1:3) using a SAS macro [22]. Comparison of AMH
levels in women living with HIV and control women was performed
with an unpaired t-test. Normal distribution was assessed by Q-Q
plots.
A simple linear regression was performed to predict AMH levels
based on independent variables, chosen a priori: age, CD4 cell
count, prior AIDS diagnosis and antiretroviral treatment. A multiple
linear regression model was used for all the variables.
Antiretroviral treatment was divided into three possible regimens:
(1) Two nucleoside reverse transcriptase inhibitors (NRTIs) + one
non-nucleoside reverse transcriptase inhibitor (NNRTI); (2) Two
NRTIs + one protease inhibitor (PI); or (3) Other combinations.
PLWH* included in the
Danish HIV Cohort
n=6491
PLWH attending other
centres than Copenhagen
University Hospital,
Hvidovre or Rigshospitalet
n=1948 PLWH attending
Copenhagen University
Hospital, Hvidovre or
Rigshospitalet
n=4543
WLWH***
n=939
MLWH**
n=3604
White WLWH
n=496
Non-white ethnicity
n=443
Age 20–40 years and with
suppressed HIV viral loads
n=152
Age <20 years or >40 years
and HIV viral load ≥50
copies/mL
n=344
WLWH with no HBV or HCV
co-infection
n=97
WLWH co-infected with
HBV or HCV
n=55
Pregnant at sample time,
n=2
Missing samples, n=10
Gynecological surgery,
n=1
Total
 WLWH who met inclusion
criteria
n=84
Figure 1. Flowchart illustrating inclusion process of 84 white, non-hepatitis B virus
(HBV)-, non-hepatitis C virus (HCV)-infected, 20–40-year-old women living
with HIV with HIV RNA ≤50copies/mL for minimum of 6 months. *PLWH:
people living with HIV; **MLWH: men living with HIV; ***WLWH: women
living with HIV
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SAS statistical software version 9.3 (SAS Institute Inc., Cary, NC,
USA) was used for data analysis and P-values below 0.05 (two-
sided) were considered statistically significant.
Ethical statement
The study was approved by the Danish National Ethical Committee
(H-16021157, H-B-2007-129) and the Danish Data Protection
Agency (2012-58-0004, 2008-41-1881).
Results
Pilot study
There was no statistically significant difference (95% confidence
interval [CI] −0.27−0.64, P=0.38) between AMH levels in EDTA
plasma and serum samples. The difference between EDTA and
serum ranged from 0.1% (+0.02 pmol/L) to 6.8% (−1.35 pmol/L),
with a median difference of 0.435 pmol/L. Based on these results,
it was considered acceptable to compare data using EDTA versus
serum samples for AMH measurements.
Demographic data
As seen in Table 1, a total of 84 white women living with HIV and
252 white control women between 20 and 40 years of age were
included. The median age of the women living with HIV was 33.5
years (IQR 30.6−35.3) and the median age of the control women
was 33.2 years (IQR 30.6−35.5). For the women living with HIV,
median duration of HIV diagnosis was 6.6 years (IQR 3.3−10.9).
Among the 84 women living with HIV, 71 (85%) had CD4 cell
counts above 350 cells/μL and 76 (91%) were on antiretroviral
treatment (Table 1). All women had undetectable HIV RNA, and
the eight (9%) allegedly not on antiretroviral treatment, were most
likely on treatment, but this information was not recorded in the
DHCS. The majority of the PI-based regimens (n=23/38; 61%)
were based on boosted PIs.
For the majority of women living with HIV, mode of transmission
was heterosexual (n=76; 91%), 68 (80%) indicated Europe as the
most probable place of transmission, and 12 (14%) had prior
AIDS-defining diagnoses (Table 1).
Anti-müllerian hormone levels
Table 2 shows the AMH levels in the women living with HIV and
the control women. The median AMH level in the youngest age
group (20–29 years) among women living with HIV was
23.0 pmol/L (95% CI 16.12−29.83) and 29.5 pmol/L (95% CI
24.10−34.83) among the control women (p=0.20). In the age
group 30–34 years, the median AMH levels were 17.2 pmol/L
(95% CI 13.47−21.09) and 21.0 pmol/L (95% CI 18.08−23.88),
respectively (P=0.18). In the age group 35–40 years the median
AMH levels were 12.6 pmol/L (95% CI 8.72−16.52) and
16.8 pmol/L (95% CI 13.24−20.37), respectively (P=0.21). When
comparing all age groups collectively, there was a statistically
significant difference in AMH level distribution between women
living with HIV and control women, with median AMH levels of
17.23 pmol/L (95% CI 14.56−19.89) and 21.65 pmol/L (95% CI
19.50−23.81) (P=0.03), respectively.
Variables associated with AMH levels
Table 3 shows the a priori chosen variables tested for association
with AMH levels in women living with HIV: age, CD4 cell count
(cells/μL), AIDS diagnosis prior to inclusion and antiretroviral
treatment, including types of antiretroviral treatment regimens.
Age was the only variable, significantly associated with AMH levels,
with a decrease in AMH level of 0.93 pmol/L per year increase
in age (P=0.004, 95% CI −1.56−−0.30), while none of the
remaining variables wae statistically significantly associated with
AMH levels (Table 3).
Discussion
To our knowledge, this is the first case–control study comparing
AMH levels, measured with the new and improved Elecsys AMH
assay, in white women living with HIV and with a very well-defined
control group of HIV-uninfected women with no known fertility
problems. We found a statistically significant difference in AMH
levels between women living with HIV and age-matched HIV-
uninfected women, when all age groups were analysed collectively.
Furthermore, of the tested variables, we only found age to be
significantly associated with AMH levels.
Table 1. Demographic data for 84 white, non-HBV, non-HCV,
20–40-year-old women living with HIV
Demographic data WLWH (n=84) n (%)
Median age at inclusion (years, IQR) 33.5 (30.6–35.3)
Age groups (years)
20–29 18 (21.4)
30–34 43 (51.2)
35–40 23 (27.4)
Median duration of HIV (years, IQR) 6.6 (3.3–10.9)
Region of transmission
Denmark 51 (60.7)
Europe 17 (20.2)
Africa 4 (4.8)
Asia 2 (2.4)
Other 1 (1.2)
Missing 9 (10.7)
Mode of transmission
Heterosexual 76 (90.5)
IDU 2 (2.4)
Blood transfusion 2 (2.4)
Missing 4 (4.7)
Latest CD4 count cells/μL
<350 13 (15.5)
≥350 71 (84.5)
ART
Yes 76 (90.5)
No 8 (9.5)
ART regimen
Regimen 1 (2 NRTIs + 1 NNRTI) 21 (25.0)
Regimen 2 (2 NRTIs + PI) 38 (45.3)
Regimen 3 (other) 17 (20.2)
No ART 8 (9.5)
AIDS prior to inclusion
Yes 12 (14.3)
No 72 (85.7)
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral
treatment; HIV: human immunodeficiency virus; HBV: hepatitis B virus;
HCV: hepatitis C virus; IDU: intravenous drug use; IQR: interquartile
range; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI:
nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
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Demographic data
The present study population represents well-treated women living
with HIV, living in Denmark, as all of the 84 participants had fully
suppressed HIV RNA viral loads (≤50 copies/mL) and 91% were
on antiretroviral treatment. The study population does differ from
the general population of women living with HIV in Denmark in
one important respect: all of the study participants were white,
while approximately 45% of the total population of women living
with HIV in Denmark originate from sub-Saharan Africa [16,23].
Some studies suggest that AMH varies with ethnicity [9,24,25].
An American study of 809 (628 HIV-infected, 181 HIV-uninfected)
white, black and Hispanic women, with no known fertility issues,
showed that AMH levels were significantly lower in women of black
ethnicity, compared to women of white ethnicity [9]. That, as well
as the HIV-uninfected women being white, was the basis for our
decision to include only white women living with HIV.
AMH levels in women living with HIV and control women
Whenwe compared all age groups, we found a statistically significant
difference in mean AMH levels between women living with HIV
and control women (P=0.03). Similar to our findings, Ohl et al.
[5] showed a 23% reduction in AMH levels among 78 women living
with HIV, with a mean age of 34 years (18−45), compared to
expected, age-specific levels. Most of the women living with HIV
studied had fully suppressed HIV viral loads and regular menstrual
cycles [5]. The authors did not find any
association between CD4 cell counts andAMH
[5]. Also supporting our results, Scherzer et
al. [6] found 16% lower AMH levels among
2621 women living with HIV (ages 19–80
years), although after adjusting for age, race,
smoking, hormonal contraceptive use,
amenorrhea, weight loss, current and nadir
CD4 cell counts, nadir CD8 andT lymphocyte
counts, AMH was higher than in 941 HIV-
uninfected control women. The authors
concluded that a good immune system was
associated with a good ovarian reserve [6].
Of note, AMH measurements were conducted
using the previous method (ELISA kit) [6].
Similar to the studies mentioned above,
another study showed that 201 women living
with HIV, requesting assisted reproductive
technology, had significantly (P=0.001) lower
levels of AMH, compared to 603 age- and
cause of infertility-matched, HIV-uninfected
women [26]. Increasing CD4 cell counts were
associated with an increase in AMH levels.
Also, it was recently shown that AMH can be
used for predicting age at menopause in
women living with HIV [10]. This may be an
important factor when counselling fertility
planning in women living with HIV, as
it seems that AMH may be used as a
‘reproductive lifespan’ measurement.
The AMH values in both women living with HIV
and control women were within reference limits,
indicating that both groups have normal AMH
values, although consistently lower in the
women living with HIV group [27]. The clinical
relevance of this may be questionable; however,
as HIV infection has been associated with
preterm onset of menopause, the reducedAMH
values in this group of women living with HIV
may have a significance in terms of ovarian reserve pool quantification
and for the prediction of early onset of menopause [10].
Variables associated with AMH levels
As expected, we found that increasing age was associated with
decreasing levels of AMH [1]. We did not find any significant
association betweenAMH levels and the remaining variables, including
CD4 cell counts. The association between AMH levels and fertility
are uncertain, and it seems that AMH is an indeterminate predictor
of pregnancy and live birth after IVF [28]. Only a few studies have
reported on natural fertility and AMH, and it is unclear what clinical
significance on fertility the reduced AMH levels in our study have,
as no information on previous pregnancies was available [29–31]. We
have previously shown that women living with HIV in Denmark
conceive naturally, and national and international guidelines are leaning
towards natural conception among women with fully suppressed viral
loads [32,33]. It is possible that the fertility of women living with HIV
has improved significantly since the introduction of effective
antiretroviral treatment, but our study indicates that a significant
difference in AMH levels between women living with HIV and
HIV-uninfected women remains. Further studies should focus on
clarifying whether this difference is clinically relevant.
The main strengths of this study were the two relatively
homogenous populations, both in ethnicity and age. Another
Table 2. Mean AMH levels in 84 white, non-HBV, non-HCV, 20–40-year-old women living
with HIV and 252 age-matched control women
Age group Cases WLWH Control women P-value
20–29 years n (%) 18 (21.4%) 54 (21.4%)
AMH pmol/L, mean (95% CI) 22.97 (16.12–29.83) 29.46 (24.10–34.83) 0.20
30–34 years n (%) 43 (51.2%) 129 (51.2%)
AMH pmol/L, mean (95% CI) 17.28 (13.47–21.09) 20.98 (18.08–23.88) 0.183
35–40 years n (%) 23 (27.4%) 69 (27.4%)
AMH pmol/L, mean (95% CI) 12.62 (8.72–16.52) 16.81 (13.24–20.37) 0.21
All age groups n (%) 84 (100%) 252 (100%)
AMH pmol/L, mean (95% CI) 17.23 (14.56–19.89) 21.65 (19.50–23.81) 0.03
CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; WLWH: women living with
HIV.
Table 3. Variables associated with anti-müllerian hormone in 84 white, non-HBV, non-HCV,
20–40-year-old women living with HIV. Simple linear regression analysis with the
following variables: age, latest CD4 cell count, prior AIDS-defining diagnosis
(reference: no prior AIDS diagnosis), antiretroviral treatment (reference: yes, receiving
treatment), and antiretroviral treatment regimen (reference: Regimen 1)
Variables associated with
AMH levels All age groups
Average change 95% CI P-value
Age (years) −0.93 −1.56–−0.30 0.004
CD4 count (cells/μL) 0.01 −0.002–0.017 0.141
AIDS prior to inclusion −1.85 −9.50–5.81 0.633
Antiretroviral treatment 4.39 −4.70–13.48 0.340
Antiretroviral regimens
Regimen 1
Regimen 2 1.80 −4.79–8.39 0.588
Regimen 3 −1.53 −9.43–6.38 0.702
AIDS: acquired immunodeficiency syndrome; AMH: anti-müllerian hormone; Average change:
estimate of average change (β); HBV: hepatitis B virus; HCV: hepatitis C virus; IDU: injecting drug
user; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse
transcriptase inhibitor; PI: protease inhibitor; Regimen 1: 2 NRTIs + 1 NNRTI; Regimen 2: 2 NRTIs
+ PI; Regimen 3: other.
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strength was that all AMH analyses were performed with the new
and improved Elecsys AMH assay, generating reliable results. Also,
all women living with HIV had fully suppressed HIV RNA viral loads,
and the vast majority had high CD4 cell counts, thus eliminating
poor immune function as a possible confounder.
An important limitation to this study is that information on
hormonal contraceptive use, which has previously been shown to
reduce AMH levels, was not possible to obtain. However, our
previous findings in the same population of women living with
HIV show a general low usage [23,34]. In addition, no information
on other factors that may influence AMH levels, such as BMI or
smoking habits, were available.
Another limitation is the possibility of selection bias, as control
women with symptoms of possible polycystic ovarian syndrome
were excluded, but women living with HIV with similar symptoms
were not. This may have resulted in higher AMH levels in control
women, compared to women living with HIV.
Finally, it has previously been shown that freeze–thaw cycles and
sample storage at −20°C or −80°C for up to 9 months have no
impact on AMH levels, and our analyses showed no signs of sample
degradation, despite freeze-time up to 19 years [20].
Our study shows that well-treated, white women living with HIV in
Copenhagen, Denmark have significantly lower AMH levels than
age-matched, HIV-uninfected control women.The clinical significance
of this reduction in AMH levels remains unclear, and further studies
are needed to establish the role of AMH in fertility assessments.
However, as AMH may be used for predicting age at menopause in
women living with HIV, our study may suggest that this group of
women are at risk of entering menopause earlier than control women.
This is important when health personnel provide counselling
concerning menopausal symptoms and related co-morbidities.
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